CONVINCE trial results show that high dose haemodiafiltration reduces mortality of kidney dialysis patients.
To find out more about the CONVINCE Clinical Trial, please check our Q&A section
End stage kidney disease
End stage kidney disease (ESKD) ranks among the most severe chronic non-communicable diseases with an unmet medical need.
Haemodialysis (HD) treatment is the current standard of care for the vast majority of patients with ESKD. HD is associated with high risks of fatal and non-fatal cardiovascular disease, for infections, hospitalisation and low quality of life.
Improvement in the currently available standard is urgently needed. The CONVINCE study aims to determine the best possible dialysis treatment by comparing high-dose HDF versus conventional high-flux HD treatment by carrying out a prospective randomised controlled clinical trial addressing clinical endpoints, quality of life and a cost-utility analysis.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754803